Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.35 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.35 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17863581 | 0.87 | MAPK1 (0.37) | MEN1KMT2ACYP2C19MAPK1 | |
| SCHEMBL18134367 | 0.87 | LPL (0.46) | MEN1KMT2ACYP2C19KDM1AMAOB | |
| SCHEMBL18371205 | 0.82 | SLC5A2 (0.40) | MEN1KMT2ACYP2C19KDM1AMAOA | |
| SCHEMBL18134371 | 0.80 | LPL (0.41) | MEN1KMT2AMAOA | |
| SCHEMBL28475250 | 0.79 | L3MBTL1 (0.46) | MEN1KMT2AMAPK1LMNAPOLB | |
| SCHEMBL18371213 | 0.79 | LPL (0.40) | MEN1KMT2AMAOA | |
| SCHEMBL18371202 | 0.79 | SLC5A2 (0.38) | CYP2C19KDM1AMAOACYP3A4 | |
| SCHEMBL18371209 | 0.79 | LPL (0.40) | MEN1KMT2AMAOA | |
| SCHEMBL9946119 | 0.78 | ACHE (0.38) | MEN1KMT2AMAPK1LMNAALDH1A1 | |
| SCHEMBL24452337 | 0.78 | LPL (0.39) | MEN1KMT2ACYP2C19KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-19 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MEN1 4590/4885KMT2A 4328/4885CYP2C19 3767/4885 |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MEN1 791/4885KMT2A 3109/4885CYP2C19 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.